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Abstract
Background: Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the
heart, metabolises arachidonic acid to biologically active eicosanoids. One of the CYP2J2 products, 11, 12-
epoxyeicosatrienoic acid, has several vasoprotective effects. The CYP2J2-G-50T-promotor polymorphism
decreases gene expression and is associated with coronary artery disease. This association supports the
vascular protective role of CYP-derived eicosanoids in cardiovascular disease. In the present study, we
investigated the influence of this polymorphism on survived myocardial infarction in two study groups of
patients with on average high cardiovascular risk profile.
Methods: The CYP2J2 polymorphism was genotyped in two groups of patients that were collected with
the same method of clinical data collection. Data from 512 patients with sleep apnoea (group: OSA) and
on average high cardiovascular risk profile and from another 488 patients who were admitted for coronary
angiography (CAR-group) were evaluated for a potential correlation of the CYP2J2 polymorphism G-50T
and a history of myocardial infarction. The G-50T polymorphism of the CYP2J2 gene was genotyped by
allele specific restriction and light cycler analysis.
Results: The T-allele of the polymorphism was found in 111 (11.1%; CAR-group: N = 65, 13.3%; OSA: N
= 46, 9.0%). 146 patients had a history of myocardial infarction (CAR: N = 120, 24.6%; OSA: N = 26, 5.1%).
Cardiovascular risk factors were equally distributed between the different genotypes of the CYP2J2 G-
50T polymorphism. In the total group of 1000 individuals, carriers of the T-allele had significantly more
myocardial infarctions compared to carriers of the wild type (T/T or G/T: 21.6%; G/G: 13.7%; p = 0.026,
odds ratio 1.73, 95%-CI [1.06–2.83]). In the multivariate logistic regression analysis the odds ratio for a
history of myocardial infarction in carriers of the T-allele was 1.611, 95%-CI [0.957–2.731] but this trend
was not significant (p = 0.073).
Conclusion: In presence of other risk factors, the CYP2J2 G-50T failed to show a significant role in the
development of myocardial infarction. However, since our result is close to the border of significance, this
question should be clarified in larger, prospective studies in the future.
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Background
The human Cytochrome P450 enzyme, CYP2J2, is abun-
dantly expressed in coronary artery endothelial and
smooth muscle cells as well as in cardiac myocytes [1].
Cytochrome P450 epoxygenases metabolise arachidonic
acid to epoxyeicosatrienoic acids (EETs). These eicosa-
noids exert anti inflammatory [2-4], vasodilator, [5-7],
antithrombotic, antimigratory, antioxidant, and antiap-
optotic effects [3,8].
The CYP2J2 G-50T polymorphism is a relatively frequent
polymorphism that was observed in the proximal pro-
moter region of the gene, which causes a loss of transcrip-
tion factor binding site Sp1. This leads to a reduced
interaction of this transcription factor with the CYP2J2
promoter. In vascular endothelial cells, the G-50T poly-
morphism was associated with a 50% reduction in
CYP2J2 promoter activity compared with that of the wild
type promoter. As a consequence, individuals with the G-
50T polymorphism had significantly lower plasma con-
centrations of 14,15-DHET (dihydroxeicosatrienoicacids,
the measurable, stable metabolite of 14, 15-EET), com-
pared with wild type individuals [9]. The relevance of
these findings for human atherosclerosis was assessed in a
cohort of N = 500 patients (age limit, <65 years) with and
without coronary artery disease (CAD). Individuals with
angiographic exclusion of CAD had a homozygous or het-
erozygous CYP2J2 promoter polymorphism in 10.6%,
while it was found in a significantly higher proportion of
17.3% in individuals with coronary stenosis > 50. After
adjustment for conventional risk factors, age and sex, the
odds ratio for having CAD was still significantly higher for
carriers of the T allele (odds ratio: 2.23) [9]. It is suggested
that the CYP2J2 dependent anti inflammatory, anti
thrombotic and vasodilatative mechanisms may also play
a role in the development of myocardial infarctions. How-
ever, the studies so far published yielded conflicting
results regarding the correlation of the G-50T polymor-
phism and myocardial infarction [10,11]
The present study investigates, whether the CYP2J2 G-50T
polymorphism promotes the development of myocardial




The Polymorphism was genotyped in two study groups of
patients that were collected at the University of Bochum in
order to investigate predisposing genetic factors for the
development of cardiovascular risk factors, coronary heart
disease and myocardial infarction. The data collection was
performed with the same patient's questionnaire and the
same design of the ACCESS-database. Therefore the cut off
values and criteria for the determination of the different
risk factors were the same in both groups. Dyslipidemia
was diagnosed by patient recall and when patients were
either taking lipid lowering drugs or had dyslipidemic
serum level values. For blood analysis, the following cut-
off values were defined as abnormal: total cholesterol ≥
200 mg/dl, triglycerides ≥ 180 mg/dl, HDL-C ≤ 40 mg/dl,
and LDL-C ≥ 150 mg/dl. Diabetes was defined by patient
recall and also if patients were taking antidiabetic medica-
tion or insulin therapy. The diagnosis hypertension was
established if patients were either on antihypertensive
medication or if the mean of three measured systolic BP
exceeded 140 mmHg or the diastolic BP 90 mmHg,
respectively. The diagnosis myocardial infarction was
established by patient recall and was confirmed by view-
ing the patient records (i.e. ECG, echocardiography).
All patients gave informed consent and explicitly pro-
vided permission for DNA analysis and collection of rele-
vant clinical data. The study protocols were approved by
the local ethics committee (University of Bochum, Ger-
many).
Patients in the obstructive sleep apnea study group (OSA
group, N = 512) were consecutively enrolled during the
years 1999 to 2001 in the sleep laboratory of the Marien-
hospital, Herne, Ruhr-University Bochum, Germany. The
patients were admitted to the hospital because of a history
of apneas, snoring or hypersomnic symptoms like day
time tiredness or impairment of cognitive functions.
Detailed information about the determination of cardiac
risk factors and polysomnography were described exten-
sively in previous publications [12,13] The subjects of the
other group (CAR group, N = 488) were consecutive
patients encountered in the cardiac catheterisation labora-
tory in the St. Josef Hospital of the Ruhr-University
Bochum from October 2001 to August 2002. The com-
plete clinical history, including cardiovascular risk factors,
was obtained from all study subjects by use of the same
data collection method as in the OSA group (see above).
Genotyping
Patient DNA was isolated from whole-blood samples by
the phenolchloroform extraction method. The promoter
polymorphism G-50T was genotyped by a restriction
endonuclease digestion system. The G-50T polymor-
phism creates a novel restriction site for the AluI endonu-
clease (recognition sequence AGCT). PCR (using the
following primers: sense, 5-TTTTCTGAGACCGGT-
GCGTG-3; antisense: 5-TAGGAGAGTCCGAGGATGGA-
3) yielded a 242-bp product including the polymorphism.
Incubation with AluI resulted in 2 fragments (99 and 143
bp) in the PCR products, containing the T-allele, but not
in those with the wild type. Results of restriction analysis
were confirmed by Light-Cycler PCR using the followingBMC Cardiovascular Disorders 2008, 8:41 http://www.biomedcentral.com/1471-2261/8/41
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PCR-primers and the following specific sensor and anchor
primers:
Forward-Primer: 5' TGCGTGTCCTCCCGGGAAT 3'
Reverse-Primer: 3 GGAGAGZCCGAGGATGGACCA 5'
Results of restriction analysis were confirmed by Light-




The genotypes of the CYP2J2 G-50T polymorphism were
identified by the different melting temperatures for the G
(61°C) and the T allele (66°C).
Statistical analysis
Results are presented as means +/-SD. All reported P-val-
ues are two-tailed. Statistical analyses were performed
with the computer software SPSS for Windows (SPSS, Chi-
cago, IL, USA). Demographic characteristics of the
patients were compared between the different genotypes
by using a chi square test and were considered signifi-
cantly different if the p-values were <0.05. Because of the
rare incidence of homocygote T-allele carriers, heterocy-
gote and homocygote T-allele genotypes of the CYP2J2 G-
50T polymorphism were pooled to one group.
Comparisons between the CYP2J2 G-50G group and the
CYP2J2 G-50T/T-50T group were performed by students t-
test for unpaired samples.
The influence of the T-allele (G-50T/T-50T) on myocar-
dial infarction was then analysed in a multivariate logistic
regression model, adjusted for diabetes, dyslipidemia,
hypertension, gender, smoking and age.
Results
The T-allele of the polymorphism was found in 111
(11.1%, CAR: N = 65, 13.3%; OSA: N = 46, 9.0%). Cardi-
ovascular risk factors were equally distributed between the
different genotypes of the CYP2J2 G-50T polymorphism
(Table 1).
In the total group 146 patients had a history of myocardial
infarction (CAR: N = 120, 24.6%; OSA: N = 26, 5.1%). In
the t-test for unpaired samples the group of patients carry-
ing the T-allele had significantly more myocardial infarc-
tions compared to carriers of the wild type (T/T or G/T:
21.6% vs. G/G: 13.7%; chi-square-test: p = 0.026; odds
ratio: 1.73, 95%-CI [1.06–2.83] Table 2).
A multivariate logistic regression analysis between the risk
factors and myocardial infarction could only include 890
patients because of missing or invalid information about
smoking habits in 110 patients. After multivariate regres-
sion the odds ratio for myocardial infarction in carriers of
the T allele slightly decreased 1.611, 95%-CI [0.957–
2.731]. However, although other risk factors did not differ
between the genotypes, the p value of this relationship
barely exceeded the border of significance (p = 0.073) as
shown in Table 3.
Discussion
We studied the influence of the CYP2J2 G-50T polymor-
phism on the history of myocardial infarction in two
Table 1: Cardiovascular risk factors in the different genotypes of the CYP2J2 G-50T polymorphism




All 512 55.4 ± 10.6 30.9 ± 5.7 274 (53.2) 77 (15.0) 219 (42.8) 288 (71.6)
G/G 466 (91.0) 55.0 ± 10.6 30.8 ± 5.7 246 (52.8) 68 (14.6) 197 (42.3) 259 (71.0)
G/T T/T 46 (9.0) 58.3 ± 9.6 31.2 ± 5.6 28 (60.9) 9 (19.6) 22 (47.8) 29 (78.1)
P 0.045 0.621 0.295 0.368 0.468 0.34
CAR-group N = 488 All 488 65.1 ± 11.3 27.7 ± 4.1 368 (75.4) 116 (23.8) 299 (61.3) 329 (67.4)
G/G 423 (86.7) 65.3 ± 11.3 27.8 ± 4.2 321 (75.9) 100 (23.6) 261 (61.7) 282 (66.7)
G/T T/T 65 (13.3) 63.5 ± 11.2 27.0 ± 4.1 47 (72.3) 16 (24.6) 38 (58.5) 47 (72.3)
P 0.240 0.153 0.533 0.854 0.618 0.36
All N = 1000 All 1000 60.1 ± 12.0 29.2 ± 5.1 642 (64.2) 193 (19.3) 518 (51.8) 617 (69.3)
G/G 889 (88.9) 59.9 ± 12.1 29.3 ± 5.2 567 (63.8) 168 (18.9) 458 (51.5) 541 (68.7)
G/G T/T 111 (11.1) 61.4 ± 10.8 28.6 ± 6.1 75 (67.6) 25 (22.5) 60 (54.1) 76 (74.5)
P 0.220 0.227 0.433 0.362 0.614 0.23
Abbreviations: OSA-Patients: Patients with obstructive sleep apnea, CA-Patients: patients, referred to coronary angiography, BMI: body mass index, 
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study groups. In order to achieve a sufficient number of
patients, a pooled analysis from 2 different study groups
was performed. Both study groups represent patients with
high cardiovascular risk profiles. The same criteria for car-
diovascular risk factor classification were used in these
groups and genotyping was performed with the same
methods. Thus, of 1000 patients, a relative high number
of 146 patients had a history of myocardial infarction. As
expected, the OSA group showed a lower rate of myocar-
dial infarction than the CAR group which was collected in
the catheterization laboratory of a cardiology unit. How-
ever, the cardiovascular risk factor profile of OSA patients
is similar to those patients presenting in hospital with sus-
pected coronary heart disease. In addition, several studies
have shown that OSA itself aggravates conventional risk
factors for myocardial infarction, especially arterial hyper-
tension [13,14] dyslipidemia [12], and insulin resistance
[15]. Further, OSA independently increases the risk of
sudden fatal and non fatal cardiovascular events [16]. This
may be the reason for the relative high percentage of myo-
cardial infarctions (5.1%) in the comparatively young
OSA group with an age of on average 55 years.
Although multivariate regression analysis could not show
a significant relation between myocardial infarction and
the G-50T polymorphism, our results do not definitely
exclude a role of this polymorphism in the pathogenesis
of myocardial infarction. Importantly, approximately
30% or more of those individuals with myocardial infarc-
tion die before hospital admission. Therefore a definite
answer regarding the potential role of the CYP2J2 pro-
moter polymorphism in this regard can only be achieved
by prospective analysis of a cohort with an adequate fol-
low-up period.
The CYP2J2 G-50T polymorphism via lower EET serum
levels may negatively influence many pathways which are
suspected to cause myocardial infarction. Since the poly-
morphism has been detected recently, there are currently
few population-based studies about the association with
myocardial infarction. However, in a recent study, Liu and
co workers found significantly more carriers of the T-allele
in a group of 200 young patients with acute myocardial
infarction, compared with a group of age matched con-
trols [11]. In addition they could demonstrate in vitro that
in cells with the T-allele but not in the wild type cells, nic-
otine significantly reduced promoter activity. EET metab-
olites were significantly lower among CYP2J2 T-allele
carriers, compared to carriers of the wild type.
Smoking and this variant had a significant interactive and
synergistic effect on the development of myocardial inf-
arction.
In contrast to the above mentioned results we could not
show an independent synergistic interaction between the
T-allele, smoking and myocardial infarction. One impor-
tant reason for this may be the younger age in the study
group of Liu et al. It is well known that genetic predispo-
sition in cardiovascular disease is predominantly relevant
in younger age [17].
Another study could not confirm a correlation between
the G-50T promoter polymorphism and myocardial inf-







G/G G/T or T/T G/G G/T or T/T G/G G/T or T/T
N 466 46 423 65 889 111
MI 21 (4.5%) 5 (10.9%) 101 (23.9%) 19 (29.2%) 122 (13.7%) 24 (21.6%)
P 0.061 0.351 0.026
Abbreviation: MI = Myocardial infarction.
Table 3: Multivariate logistic regression between risk factors and myocardial infarction
Myocardial Infarction adjusted
Odds ratio (Confidence Interval) p
CYP2J2 G/T or T/T 1.611 (0.957 – 2.731) 0.073
Diabetes 1.529 (0.995 – 2.349) 0.052
Hypertension 1.126 (0.725 – 1.748) 0.597
Dyslipidemia 1.644 (1.100 – 2.455) 0.015
Age 1.049 (1.030 – 1.069) <0.001
Smoking 1.622 (1.233 – 2.125 <0.001
Gender 1.311 (0.844 – 2.099) 0.219BMC Cardiovascular Disorders 2008, 8:41 http://www.biomedcentral.com/1471-2261/8/41
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arction in a large cohort of patients [10]. The reason for
these conflicting results remain at least in part unclear, as
in other genotype association studies. One possible expla-
nation are differences in the methods used. Our previous
experience has shown that genotyping with the restriction
endonuclease method (using the enzyme AluI) is unrelia-
ble in some cases. Light cycler analysis in the case of the
G-50T polymorphism is more reliable compared to direct
sequencing. Given the relative small number of individu-
als with the polymorphism, the method of genotyping
used might contribute to different results.
As mentioned above, genetic predisposition to myocar-
dial infarction is predominantly relevant in younger age
[17]. While Liu et al. [11] found significant results in a
younger study group (age < 45), the insignificant results of
the LURIC Study [10] were collected in group with a mean
age of 64 years. The same analysis in our collective with a
mean age 58 years generates a result at the border of sig-
nificance. Therefore the level of significance may indeed
correlate inversely with the age of the study group. This
may be another reason for the different results on the
genetic impact of the CYP2J2 G-50T polymorphism on
myocardial infarction.
Observing the overall group of 1000 patients, a history of
myocardial infarction is the only phenotype showing a
significant difference between the genotypes of the inves-
tigated polymorphism. Although the results of the multi-
variate analysis are not significant, this trend, in our view,
may indicate a role of the CYP2J2 G-50T polymorphism
with its anti-inflammatory, vasodilatative and antithrom-
botic relevance in the genesis of myocardial infarctions.
However, larger, prospective trials in younger patients are
necessary to solve this question.
Limitations
In the present study, we retrospectively observed the his-
tory of myocardial infarctions in a group of 1000 patients.
Fatal cardiac events could not be considered in this study.
The exact coronary status was not included in the analysis
because coronary catheterisation was not performed in
the OSA patients. In these patients the diagnosis of coro-
nary heart disease was established by patient recall and
searching of patients documents and thus it is not as reli-
able as the clinical diagnosis available in the CAR group.
A further limitation of our work is the two-group ascer-
tainment and the joint analysis. In addition the total
number of patients is comparatively small for genetic
association studies and therefore the power to detect an
association may be low.
Conclusion
In presence of other risk factors, the CYP2J2 G-50T failed
to show a significant role in the development of myocar-
dial infarction. However, since our result is close to the
border of significance and because positive results were
found in a younger study group, further research is neces-
sary. Prospective studies with on average younger patients,
defined methods and sufficient follow-up periods,
observing nonfatal and fatal coronary events should be
performed in the future to clarify this question.
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